Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams /

Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board exam...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores principales: Worden, Francis P. (Autor), Perissinotti, Anthony J. (Autor), Marini, Bernard L. (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Demos Medical, [2016]
Temas:
Antineoplastic agents > Physiological effect > Problems, exercises, etc.
Tumors > Chemotherapy > Problems, exercises, etc.
Antineoplastic Agents > pharmacology
Neoplasms > drug therapy
Anticancéreux > Effets physiologiques > Problèmes et exercices.
Tumeurs > Chimiothérapie > Problèmes et exercices.
MEDICAL > Pharmacology.
Antineoplastic agents > Physiological effect
Tumors > Chemotherapy
Examination Questions
Problems and Exercises
exercise books.
Problems and exercises
Problems and exercises.
Problèmes et exercices.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites
  • AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies
  • Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index

Ejemplares similares